BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models
Anastasia Wyce(GlaxoSmithKline (United States)), Peter J. Tummino(Intarcia Therapeutics (United States)), Charles F. McHugh(GlaxoSmithKline (United States)), Peter D. Craggs(GlaxoSmithKline (United Kingdom)), Romain Gosmini(Galapagos (France)), Yuchen Bai(The University of Melbourne), Rab K. Prinjha(GlaxoSmithKline (United Kingdom)), Dashyant Dhanak(Wilmington University), Michael T. McCabe(GlaxoSmithKline (United States)), Lydia V. Sanchez(GlaxoSmithKline (United States)), Chun‐wa Chung(GlaxoSmithKline (United Kingdom)), Karen M. Kennedy-Wilson(GlaxoSmithKline (United States)), Kimberly N. Smitheman(GlaxoSmithKline (United States)), Olena Barbash(GlaxoSmithKline (United States)), Nigel J. Parr(GlaxoSmithKline (United Kingdom)), Gopinath Ganji(GlaxoSmithKline (United States)), Susan Korenchuk(GlaxoSmithKline (United Kingdom)), Kurt R. Auger(Research Triangle Park Foundation), BaoChau Le(GlaxoSmithKline (United States))
Cited by 205
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
|Nature|2011|1.5k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848